Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Clinical trial NCT06860529 · RECRUITING

Trial details

NCT number: NCT06860529
Sponsor: Henan Cancer Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HR+/HER2- Breast Cancer

Start date: 2025-04-15
Primary completion: 2028-03-31
Enrollment: 357

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.